Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer…

Overview of attention for article published in Cancer (0008543X), June 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

news: 1 news outlet

twitter: 8 X users

Readers on

mendeley: 110 Mendeley

So far, Altmetric has seen 10 X posts from 8 X users, with an upper bound of 58,212 followers.

RT @JournalCancer: Randomized phase II trial of 2 neoadjuvant endocrine therapies for HR+/HER2- breast cancer https://t.co/SaL0mDXUgW https…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 6 additional X posts.